Answers are grounded in this paper and cite their sources.
There has been recent debate about the risks and benefits of the use of thiazolidinediones (rosiglitazone and pioglitazone) to treat diabetes. Similar to all other drugs used to treat diabetes, thiazolidinediones were approved by drug regulatory bodies based on their ability to improve glycemic
No takes yet. Share an insight, caveat, or question.
Lorraine L. Lipscombe (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: